文献速递淋巴瘤造血干细胞移植与细胞治疗

复发/难治性霍奇金淋巴瘤PD-1抑制剂后化疗:结局与克隆演化动态

Chemotherapy after PD-1 inhibitors in relapsed/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamics.
PubMed 文献 · Br J Haematol · 2022-04-25

本回顾性研究分析28例复发/难治性经典霍奇金淋巴瘤患者经检查点抑制剂失败后化疗再挑战的疗效,23例(82%)达完全缓解,3例(11%)达部分缓解,25例后续接受异基因造血干细胞移植,中位随访21个月时中位无进展生存期和总生存期均未达到。

要点

  • 28例CPI失败后化疗再挑战,23例(82%)完全缓解,3例(11%)部分缓解
  • 25例后续接受异基因造血干细胞移植,中位随访21个月时中位PFS和OS未达到
  • 小样本(n=5)CALDER分析显示肿瘤演化似乎发生在首个治疗周期之前,呈线性或分支模式

核心结论

  • 检查点抑制剂治疗失败的患者可经挽救化疗有效桥接至异基因或自体造血干细胞移植。

研究设计与样本

  • 回顾性研究,纳入28例检查点抑制剂失败后接受化疗再挑战的复发/难治性经典霍奇金淋巴瘤患者。
  • 其中17例(71%)为原发难治,26例(92%)对检查点抑制剂前末次化疗难治。
  • 另采用CALDER方法对5例患者小样本探索性分析克隆演化。

主要发现

  • 化疗再挑战后23例(82%)达完全缓解,3例(11%)达部分缓解。
  • CALDER推断的肿瘤演化 seemingly 发生在首个治疗周期之前,呈线性或分支演化模式。
  • 25例后续接受异基因造血干细胞移植;中位随访21个月时中位无进展生存期和总生存期均未达到。

临床怎么用

  • 作者认为检查点抑制剂失败的患者可经挽救化疗有效桥接至异基因或自体造血干细胞移植。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Checkpoint inhibitors (CPIs) are routinely employed in relapsed/refractory classical Hodgkin lymphoma. Nonetheless, persistent long-term responses are uncommon, and one-third of patients are refractory. Several reports have suggested that treatment with CPIs may re-sensitize patients to chemotherapy, however there is no consensus on the optimal chemotherapy regimen and subsequent consolidation strategy. In this retrospective study we analysed the response to rechallenge with chemotherapy after CPI failure. Furthermore, we exploratively characterized the clonal evolution profile of a small sample of patients (n = 5) by employing the CALDER approach. Among the 28 patients included in the study, 17 (71%) were primary refractory and 26 (92%) were refractory to the last chemotherapy prior to CPIs. Following rechallenge with chemotherapy, response was recorded in 23 (82%) patients experiencing complete remission and 3 (11%) patients experiencing partial remission. The tumour evolution of the patients inferred by CALDER seemingly occurred prior to the first cycle of therapy and was characterized either by linear or branching evolution patterns. Twenty-five patients proceeded to allogeneic stem cell transplantation. At a median follow-up of 21 months, median PFS and OS were not reached. In conclusion, patients who fail CPIs can be effectively rescued by salvage chemotherapy and bridged to allo-SCT/auto-SCT.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Calabretta E, Guidetti A, Ricci F, et al. Chemotherapy after PD-1 inhibitors in relapsed/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamics. Br J Haematol. 2022. PMID: 35468225. doi:10.1111/bjh.18183

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。